NEW YORK (GenomeWeb) – Illumina expects its third quarter 2015 revenues to be lower than originally anticipated and has lowered its expected full-year revenue growth to 18 percent from its previous estimate of 20 percent, the company said after the close of the market today.

Illumina reported preliminary Q3 revenues of $550 million, a 14 percent increase from $481 million in the third quarter of 2014, but below analysts' average estimate of $568.6 million. On a constant currency basis, Q3 revenues were up 18 percent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.